<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01513525</url>
  </required_header>
  <id_info>
    <org_study_id>NN2211-1745</org_study_id>
    <secondary_id>2006-004670-27</secondary_id>
    <nct_id>NCT01513525</nct_id>
  </id_info>
  <brief_title>Comparison of Liraglutide Injected at Three Different Injection Sites in Healthy Volunteers</brief_title>
  <official_title>A Randomised, Open-label, Single Centre, Three Period Cross-over Trial in Healthy Subjects Comparing the Pharmacokinetic Profiles After Single Dose Administration of Liraglutide at Three Different Injection Sites</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novo Nordisk A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novo Nordisk A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial is conducted in Europe. the aim of this trial is to compare the pharmacokinetic
      profile of liraglutide between administrations in the thigh versus the abdomen and between
      administrations in the upper arm versus the abdomen.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2007</start_date>
  <completion_date type="Actual">May 2007</completion_date>
  <primary_completion_date type="Actual">May 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the Curve (AUC) of liraglutide for each injection site</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>AUC</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax, maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax, time to maximum concentration</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tÂ½, terminal half-life</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination rate constant</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Bioavailability</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Diabetes</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Abdomen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Thigh</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Upper arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>liraglutide</intervention_name>
    <description>Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits</description>
    <arm_group_label>Abdomen</arm_group_label>
    <arm_group_label>Thigh</arm_group_label>
    <arm_group_label>Upper arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy

          -  Good general health as judged by the Investigator based on medical history, physical
             examination including 12-lead ECG (electrocardiogram), vital signs and blood and
             urinary laboratory assessments

          -  BMI (Body Mass Index): 18.5-27.5 kg/m^2, both inclusive

        Exclusion Criteria:

          -  Known or suspected allergy to trial product(s) or related products

          -  Females of childbearing potential who are pregnant, breast-feeding or intend to become
             pregnant or are not using adequate contraceptive methods as required by local law or
             practice

          -  The receipt of any investigational drug within 3 months prior to this trial

          -  History of any clinically significant renal, hepatic, cardiovascular, pulmonary,
             gastrointestinal, metabolic, endocrine, haematological, neurological, psychiatric
             disease or other major disorders that may interfere with the objectives of the trial,
             as judged by the Investigator

          -  Impaired renal function

          -  Active hepatitis B and/or active hepatitis C

          -  Positive human immunodeficiency virus (HIV) antibodies

          -  Use of any prescription or non-prescription medication, except for paracetamol and
             vitamins

          -  History of alcoholism or drug abuse during the last 12 months.

          -  Smoking

          -  Habitual excessive consumption of methylxanthine-containing (theophylline, caffeine or
             theobromine) beverages and foods (coffee, tea, soft drinks such as red bull, cola,
             chocolate) as judged by the Investigator

          -  Excessive consumption of a diet deviating from a normal diet as judged by the
             Investigator

          -  Blood donation within the last 3 months

          -  Plasma donation within the last month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Global Clinical Registry (GCR, 1452)</last_name>
    <role>Study Director</role>
    <affiliation>Novo Nordisk A/S</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novo Nordisk Investigational Site</name>
      <address>
        <city>Neuss</city>
        <zip>41460</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://novonordisk-trials.com</url>
    <description>Clinical Trials at Novo Nordisk</description>
  </link>
  <results_reference>
    <citation>Kapitza C, Zdravkovic M, Zijlstra E, Segel S, Heise T, Flint A. Effect of three different injection sites on the pharmacokinetics of the once-daily human GLP-1 analogue liraglutide. J Clin Pharmacol. 2011 Jun;51(6):951-5. doi: 10.1177/0091270010374474. Epub 2010 Jul 29.</citation>
    <PMID>20671294</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>January 16, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 20, 2012</study_first_posted>
  <last_update_submitted>January 25, 2017</last_update_submitted>
  <last_update_submitted_qc>January 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

